Please assess the completion status of the following clinical trial:

Trial Title: Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis to house dust mite (Df, Dp), cat or dog~* More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3 at serum specific IgE level (UNICAP or MAST)~Exclusion Criteria:~* Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA) guideline~* FEV1 less than 50% of predicted value if there is comorbid asthma.~* Subject rejects the enrollment into study~* Low compliance~* Pregnancy or lactation~* Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious diseases~* Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic antidepressant, immnosuppressant including systemic glucocorticosteroid (20mg or more dose of prednisolone or equivalent dose of other steroid) within last 2 weeks~* Prior history of allergen-specific immunotherapy~* Allergic rhinitis caused by other perennial or seasonal allergen~* Vulnerable volunteer

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allergen extract (Type: ACTIVE_COMPARATOR): 0.1 ml of allergen extracts
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline, 0.1 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).